Cadrenal Therapeutics Inc

Research Cadrenal Therapeutics Inc (CVKD) on Bullrun: market cap USD 9.30M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerCVKD
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 9.30M
• Financial periodFY2025
• Net income-USD 13.24M
• Free cash flow-USD 12.61M

Valuation Snapshot

latest market cap is USD 9.30M.

About Cadrenal Therapeutics Inc

Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company that develops novel therapies for life-threatening immune and thrombotic conditions. The company is developing Tecarfarin, an oral vitamin K antagonist that is in Phase 3 clinical trial designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, and atrial fibrillation;

Frequently asked questions

What is Cadrenal Therapeutics Inc's market cap?

Cadrenal Therapeutics Inc's market capitalization is USD 9.30M.

What does Cadrenal Therapeutics Inc do?

Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company that develops novel therapies for life-threatening immune and thrombotic conditions.